The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary ...

German pharmaceutical giant Merck has completed a €3 billion ($3. 5 billion) takeover of US biopharmaceutical company ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 ...

Merck (NSE: PROR) KGaA, Darmstadt, Germany, has completed its acquisition of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a company with strong financial fundamentals and impressive revenue ...

Merck KGaA, Darmstadt, Germany has closed the acquisition of SpringWorks Therapeutics Inc. for an enterprise value of $3.4 billion.

A little over two months after it was announced, Germany-based life sciences firm Merck KGaA said Tuesday that it has ...

SpringWorks Therapeutics (SWTX) ... Merck will pay $47 per share in cash for SpringWorks, representing an equity value of about $3.9 billion or an enterprise value of $3.4 billion, ...

After months of discussion, Germany’s Merck KGaA said Monday it would buy SpringWorks Therapeutics for $47 a share in cash, a deal with an equity value of nearly $4 billion.

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said.. An announcement may come as soon as Monday, the people said, asking not to be ...

Merck (NSE: PROR) KGaA, Darmstadt, Germany, has completed its acquisition of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a company with strong financial fundamentals and impressive revenue growth ...